Tagrisso® (osimertinib) – Expanded indication
February 19, 2024 - AstraZeneca announced the FDA approval of Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Top